Avicanna Nears Break-Even in 2025, Boosts Margins and Expands Clinical Pipeline
Event summary
- Avicanna reported near break-even adjusted EBITDA of $(0.29) million for 2025, a 76% improvement from 2024.
- Revenue remained flat at $25.48 million, but gross margin expanded to 53% from 51% due to cost efficiencies.
- Launched a Phase II clinical study for osteoarthritis pain with University Health Network, funded by CIHR.
- Expanded international exports with first commercial shipments of organic cannabis flower to Switzerland and Australia.
- Introduced re+PLAY™ CBD wellness brand in the U.S. through a partnership with Harrington Wellness Brands.
The big picture
Avicanna’s near break-even performance in 2025 reflects a strategic focus on operational discipline and clinical validation. The company’s expansion into international markets and partnerships with key players like Aspeya Switzerland SA and Harrington Wellness Brands positions it to capitalize on growing demand for medical cannabis. Success in its Phase II clinical trial could further solidify its leadership in cannabinoid-based medicine.
What we're watching
- Clinical Validation
- Whether Avicanna’s Phase II osteoarthritis study will yield positive results, validating its cannabinoid-based approach.
- International Scaling
- The pace at which Avicanna can expand its international exports beyond Switzerland and Australia.
- Operational Efficiency
- How sustained cost reductions and margin expansion will impact profitability in 2026.
Related topics